drugset
drugset / Trial / NCT01833741

A Study of LUMIGAN® RC in the Clinical Setting

NCT01833741 ↗

Phase 4 Completed 1137 enrolled Allergan
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.

Timeline

Start
2009-12
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.01 % —

Indications

ocular hypertension open-angle glaucoma